Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Treatment of BRAF(V600E) mutant melanoma by small molecule drugs that target the BRAF or MEK kinases can be effective, but resistance develops invariably. In contrast, colon cancers that harbour the same BRAF(V600E) mutation are intrinsically resistant to BRAF inhibitors, due to feedback activation of the epidermal growth factor receptor (EGFR). Here we show that 6 out of 16 melanoma tumours analysed acquired EGFR expression after the development of resistance to BRAF or MEK inhibitors. Using a chromatin-regulator-focused short hairpin RNA (shRNA) library, we find that suppression of sex determining region Y-box 10 (SOX10) in melanoma causes activation of TGF-β signalling, thus leading to upregulation of EGFR and platelet-derived growth factor receptor-β (PDGFRB), which confer resistance to BRAF and MEK inhibitors. Expression of EGFR in melanoma or treatment with TGF-β results in a slow-growth phenotype with cells displaying hallmarks of oncogene-induced senescence. However, EGFR expression or exposure to TGF-β becomes beneficial for proliferation in the presence of BRAF or MEK inhibitors. In a heterogeneous population of melanoma cells having varying levels of SOX10 suppression, cells with low SOX10 and consequently high EGFR expression are rapidly enriched in the presence of drug, but this is reversed when the drug treatment is discontinued. We find evidence for SOX10 loss and/or activation of TGF-β signalling in 4 of the 6 EGFR-positive drug-resistant melanoma patient samples. Our findings provide a rationale for why some BRAF or MEK inhibitor-resistant melanoma patients may regain sensitivity to these drugs after a 'drug holiday' and identify patients with EGFR-positive melanoma as a group that may benefit from re-treatment after a drug holiday.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, adaptive feedback resistance has been a key limitation in prior clinical efforts to target the RAS-MAPK pathway.”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, RTK-driven feedback reactivation of RAS-MAPK signaling has been identified as a key driver of resistance in BRAFV600E cancers treated with BRAF inhibitors (colorectal cancer in particular) and in KRAS-mutant cancers treated with MEK inhibitors (11,12,32).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple studies have demonstrated that in BRAF V600E mutant cancers, BRAF inhibition can lead to rapid EGFR-mediated feedback activation [95,96,104].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [104]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Self-citationBRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Self-citationCOT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
Cited by
Items 601–700 of 916
Future of combination therapy with dabrafenib and trametinib in metastatic melanoma
Zia, Y., Chen, L. R., & DAUD, A. I. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1085509 · Cited by 9
“In accordance with the aggressive nature of this cancer, BRAF-mutant melanoma will develop a variety of resistance mechanisms upon exposure to combiDT [38].”
BackgroundLinking SOX10 to a slow-growth resistance phenotype
Zhang, G., & Herlyn, M. (2014) · Cell Research · doi:10.1038/cr.2014.67 · Cited by 11
Wang, K., Li, Y., Song, N., Che, X., Hou, K., Xu, L., Bai, M., Wang, Q., Wang, Y., Zhou, Y., et al. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27808 · Cited by 9
“Along with the EGFR pathway, other receptor tyrosine kinases (RTKs), such as the hepatocyte growth factor receptor mesenchymal‐epithelial transition (MET), have also been implicated in resistance to BRAF inhibitors.(18) Moreover, inhibiting MEK phosphorylation with cobimetinib increased vemurafenib efficacy in melanom…”
BackgroundTargeting complex, adaptive responses in melanoma therapy
Cheng, P. F., Levesque, M. P., Dummer, R., & Mangana, J. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101997 · Cited by 9
Stagno, A. M., Vari, S., Annovazzi, A., Anelli, V., Russillo, M., Cognetti, F., & Ferraresi, V. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.645008 · Cited by 10
“org 6 who are candidates for rechallenge are reversible, hence, after a ‘drug holiday’ some patients may regain sensitivity (35).”
BackgroundComputational Model of Heterogeneity in Melanoma: Designing Therapies and Predicting Outcomes
Hodgkinson, A., Trucu, D., Lacroix, M., Cam, L. L., & Radulescu, O. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.857572 · Cited by 11
“The non-genetic nature of adaptive resistance in melanoma was first suggested by the reversibility of this process: resistant tumors can re-sensitize upon a drug holiday (6, 7).”
BackgroundPérez, C. N., Falcón, C. R., Mons, J. D., Orlandi, F. C., Sangiacomo, M., Fernandez-Muñoz, J. M., Guerrero-Gimenez, M. E., Benito, P. G., Colombo, M. I., Zoppino, F. C. M., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166801 · Cited by 12
Purwin, T. J., Caksa, S., Saçan, A., Capparelli, C., & Aplin, A. E. (2023) · iScience · doi:10.1016/j.isci.2023.107472 · Cited by 9
“We then investigated an RNA-seq dataset from Sun et al.(5) that contains two SOX10-knockdown samples and a parental control sample.”
MethodInfluentialImpact of Sun Exposure and Tanning Patterns on Next-Generation Sequencing Mutations in Melanoma
Loo, K. L., Soliman, I., Renzetti, M., Li, T., Wu, H. G., Reddy, S. S., Olszanski, A. J., & Farma, J. M. (2020) · Journal of Surgical Research · doi:10.1016/j.jss.2020.04.021 · Cited by 10
Keller, R. R., & Gunther, E. J. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.096 · Cited by 9
“More recently, oncogene overdose has been invoked to explain why some cancers, after adapting to potent targeted therapy, paradoxically depend upon continued drug treatment for maintenance and growth (Amin et al., 2015a, 2015b; Das Thakur et al., 2013; Sun et al., 2014).”
Maietta, I., Viscusi, E., Laudati, S., Iannaci, G., D’Antonio, A., Melillo, R. M., Motti, M. L., & Falco, V. D. (2024) · Cells · doi:10.3390/cells13181546 · Cited by 8
“The second important issue is that although in the first period of treatment, the use of these inhibitors yields a good therapeutic response, mechanisms of resistance usually develop within six to eight months of treatment in approximately 50% of patients [55,56].”
BackgroundJiang, C., Xie, L., Zhang, Y., Fujinaga, M., Mori, W., Kurihara, Y., Yamasaki, T., Wang, F., & Zhang, M. (2018) · Molecular Imaging · doi:10.1177/1536012118795952 · Cited by 9
Ping, S., Gong, R., Lei, K., Gong, Q., Zhang, G., & Chen, J. (2022) · Discover Oncology · doi:10.1007/s12672-022-00581-3 · Cited by 8
Clonal dynamics limits detection of selection in tumour xenograft CRISPR/Cas9 screens
Lee, T. W., Hunter, F. W., Tsai, P., Print, C. G., Wilson, W. R., & Jamieson, S. M. F. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00664-5 · Cited by 10
Dubose, E. S., Bevill, S. M., Mitchell, D. K., Sciaky, N., Golitz, B. T., Dixon, S. A. H., Rhodes, S. D., Bear, J. E., Johnson, G. L., & Angus, S. P. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1191217 · Cited by 8
Sensitivity to immune checkpoint inhibitors in BRAF/MEK inhibitor refractory melanoma
Patel, R. P., Lim, L. R. J., Saleh, R., Schenk, D., Lee, M. K., Lelliott, E. J., Rao, A. D., Arabi, S., Smith, L. K., Trigos, A., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011551 · Cited by 11
“2 Therefore, resistance mechanisms driven by either mutation are likely to exert comparable effects on ICI sensitivity, consistent with previous reports linking MAPK hyperactivation to an immunosuppressive tumor microenvironment.”
Pembrolizumab in the Management of Metastatic Melanoma
Spain, L. A., Younger, E., Hatipoglu, E., & Larkin, J. (2015) · Melanoma Management · doi:10.2217/mmt.15.33 · Cited by 9
Hanly, E. K., Tuli, N. Y., Bednarczyk, R. B., Suriano, R., Geliebter, J., Moscatello, A. L., Darżynkiewicz, Z., & Tiwari, R. K. (2015) · Oncotarget · doi:10.18632/oncotarget.6779 · Cited by 9
“ERK reactivation can be propagated by increased expression or activity of upstream signaling molecules such as receptor tyrosine kinases (RTKs) in response to VMR treatment [32–34].”
BackgroundKim, S., Kim, I. H., Jang, K. W., Kim, M. H., Sohn, J., Yun, M. R., Kang, H. N., Kang, C. W., Kim, H. R., Lim, S. M., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0375 · Cited by 9
“To our knowledge, various acquired resistance mechanisms to BRAF inhibitors have been reported to date (20): alternative splicing of BRAF (14), BRAF amplification (21), CRAF overexpression (22), and activation of EGFR signaling (15, 23, 24).”
BackgroundRetractedYang, Y. P., Wang, X., Li, Q., Zhang, M., Xu, P., Chen, Y., Yan, Y. C., & Zhang, L. (2017) · Oncology Letters · doi:10.3892/ol.2017.7330 · Cited by 8
“Good clinical outcomes have been obtained with melanoma treatments that target BRAF mutants and with MEK/ERK inhibitors.”
InfluentialZhang, Q., Liu, F., Qin, L., Liao, Z., Song, J., Liang, H., Chen, X., Zhang, Z., & Zhang, B. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-01869-4 · Cited by 10
Giannopoulou, A. F., Velentzas, A. D., Anagnostopoulos, A. K., Agalou, A., Papandreou, N. C., Katarachia, S. A., Koumoundourou, D. G., Konstantakou, E. G., Pantazopoulou, V. I., Delis, A. D., et al. (2021) · Cancers · doi:10.3390/cancers13092024 · Cited by 8
“Hitherto, described resistance mechanisms mainly include: (a) increased PDGFRβ (or IGF1R) expression [8,23–25], (b) NRAS (or MEKs) mutational activation [8,22–24], (c) dimerization of aberrantly spliced BRAFV600E [8,23,26], (d) stroma cell-derived HGF secretion [23,27], (e) EGFR upregulation [25], (f) COT (kinase) amp…”
BackgroundCold atmospheric plasma sensitizes melanoma cells to targeted therapy agents in vitro
Yan, C., Zhao, L., Zhang, X., Chu, Z., Zhou, T., Zhang, Y., Geng, S., & Guo, K. (2023) · Journal of Biophotonics · doi:10.1002/jbio.202300356 · Cited by 8
Garandeau, D., Mrad, M., Levade, T., Perrotta, C., Andrieu‐Abadie, N., & Diab‐Assaf, M. (2015) · Springer eBooks · doi:10.1007/978-3-319-20750-6_6 · Cited by 9
“Multiple changes within a given melanoma may contribute to this resistance [ 67 , 68 ], and ongoing research tries to identify new therapeutic targets to overcome this resistance.”
BackgroundEpigenetic inhibition of adaptive bypass responses to lapatinib by targeting BET Bromodomains
Stuhlmiller, T. J., Miller, S. M., & Johnson, G. L. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1052182 · Cited by 8
“Targeting the activity of responsive kinases has also shown similar synthetic lethality in other cancer types.(6-8)”
BackgroundKonstantakou, E. G., Velentzas, A. D., Anagnostopoulos, A. K., Giannopoulou, A. F., Anastasiadou, E., Papassideri, I. S., Voutsinas, G. E., Tsangaris, G. T., & Stravopodis, D. J. (2017) · Journal of Proteomics · doi:10.1016/j.jprot.2017.11.015 · Cited by 8
Francisquini, R., Berton, R., Soares, S. G., Gonçalves, D. S. P. O., Camacho, M. F., Andrade-Silva, D., Barcick, U., Serrano, S. M. T., Chammas, R. J., Nascimento, M. C. V., et al. (2020) · Journal of Proteomics · doi:10.1016/j.jprot.2020.104063 · Cited by 8
“Indeed, TGFβ signaling network is a promising pathway for pharmacological intervention in melanoma cases, since it has been implicated in the adaptive resistance to BRAF (V600E) inhibition [40].”
BackgroundFernandez, M., Sutterlüty, H., Schwärzler, C., Lemeille, S., Boehncke, W., & Merat, R. (2017) · Cancer Medicine · doi:10.1002/cam4.1091 · Cited by 8
“These patterns corroborate previous studies showing that the increased expression of pAKT and its downstream target p4EBP1 discriminate sensitive from adaptive/resistant melanoma cell lines, better than pERK1/2 expression levels [4, 6], and are also consistent with the established notion that overexpressed surface rec…”
ResultMulero‐Sánchez, A., Bosma, A. R., Visuvasam, B., Pouliopoulou, N., van de Ven, M., Proost, N., Boeije, M., Lieftink, C., Beijersbergen, R. L., Bernards, R., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03616-z · Cited by 8
“Notably, resistant cells showed decreased growth upon drug withdrawal, suggesting a drug-holi-day-like effect [36].”
Self-citationSOX10 deficiency-mediated LAMB3 upregulation determines the invasiveness of MAPKi-resistant melanoma
Han, S., Zhang, M., Qu, X., Wu, Z., Huang, Z., Hu, Y., Li, Y., Cui, L., Si, L., Liu, J., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02917-x · Cited by 7
“The regulation of MMP1, 2, 3, 13 by LAMB3 was further validated by qRT-PCR and western blotting experiments except that MMP1 expression was not apparently affected by LAMB3-KO in 1205LuR cells (Fig.”
InfluentialOn minimising tumoural growth under treatment resistance
Fischer, M. M., & Blüthgen, N. (2023) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2023.111716 · Cited by 10
Beleaua, M. A., Jung, I., Braicu, C., Milutin, D., & Gurzu, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111918 · Cited by 7
“Perhaps there is a relationship between the downregulation of miR-19a-3p and SOX10 (SRY-box transcription factor 10) suppression, both causing TGF-β signaling activation in different types of cancers [49,53].”
BackgroundTargeted CRISPR activation and knockout screenings identify novel doxorubicin transporters
Li, Y., Tan, M., Sun, S., Stea, E., & Pang, B. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00847-0 · Cited by 8
Sox10-Deficient Drug-Resistant Melanoma Cells Are Refractory to Oncolytic RNA Viruses
Abou‐Hamad, J., Hodgins, J. J., Yakubovich, E., Vanderhyden, B. C., Ardolino, M., & Sabourin, L. A. (2023) · Cells · doi:10.3390/cells13010073 · Cited by 7
“This undifferentiated state is key to cross-resistance and has been identified as a TEAD+/AP-1+/SOX9+ state [12,38].”
Backgroundp300 KAT Regulates SOX10 Stability and Function in Human Melanoma
Waddell, A. R., Grbic, N., Leibowitz, K., Wyant, W. A., Choudhury, S., Park, K., Collard, M., Cole, P. A., & Alani, R. M. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0124 · Cited by 9
“SOX10 is a neural crest lineage-specific transcription factor that is highly expressed in the melanocytic, transitory, and neural crest–like melanoma phenotypes (4) and is essential for melanoma development (5–7), rapid growth (5, 7, 8), and regulation of tumor immunogenicity (9–12).”
InfluentialRao, M., Shi, B., Yuan, Y., Wang, Y., Chen, Y., Liu, X., Li, X., Zhang, M., Liu, X., & Sun, X. (2020) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000951 · Cited by 7
BMP Signaling Promotes Neural Crest Identity and Accelerates Melanoma Onset
Gramann, A. K., Frantz, W. T., Dresser, K., Gomes, C. B. F., Lian, C. G., Deng, A., & Ceol, C. J. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.01.021 · Cited by 9
Fukushima, H., Iwata, Y., Saito, K., & Sugiura, K. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.15969 · Cited by 7
5-FU preferably induces apoptosis in BRAF V600E colorectal cancer cells via downregulation of Bcl-xL
Shi, T., Gao, M., He, M., Yue, F., Zhao, Y., Sun, M., He, K., & Chen, L. (2019) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-019-03598-5 · Cited by 8
Therapy‐Induced ECM Remodeling Creates a Transient Immune Barrier in Residual Melanoma
Hsu, C., Chen, J., Lee, K., Donahue, L. R., Kacaj, D., McDonough, S. P., & White, A. C. (2025) · Advanced Science · doi:10.1002/advs.202508451 · Cited by 12
Ott, C. A., Purwin, T. J., Chen, P., Chowdhury, S., Mellor, G. L., Luo, K., Mersky, G. L., Tiago, M., Madden, W. D. B., Varney, S. D., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64682-7 · Cited by 9
“SOX10-Received de fi cient cells are intrinsically tolerant to BRAFi and/or MEKi 13,18 ; however, targetable mechanisms of drug tolerance remain unclear.”
TGF-β, to target or not to target; to prevent thyroid cancer progression?
Karnik, I., Sutherland, R., Elson, J. L., Aspinall, S. R., & Meeson, A. P. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188752 · Cited by 6
PTRF Confers Melanoma‐Acquired Drug Resistance Through the Upregulation of EGFR
Wang, M., Cao, Y., Ren, C., Wang, K., Wang, Y., Wu, X., Mao, J., Liang, Q., Zhang, Q., Lu, H., et al. (2025) · Cell Proliferation · doi:10.1111/cpr.70086 · Cited by 9
“Indeed, several reports suggest that the EGFR signalling pathway plays a critical role in melanoma drug resistance [20–23].”
Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping
Kang, Y., Ji, Z., Li, H., & Tsao, H. (2022) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2022.03.039 · Cited by 7
Shackleford, T. J., Hariharan, S., Vaseva, A. V., Alagoa, K., Espinoza, M., Bid, H. K., Li, F., Zhong, H., Phelps, D. A., Roberts, R. D., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0625 · Cited by 7
Role of mitochondria and potential of mitochondria-targeted therapy in BRAF mutant cancer: A review
Gao, Y., & Zheng, H. S. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104484 · Cited by 8
A comprehensive review of targeting RAF kinase in cancer
Hossain, M. A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177142 · Cited by 7
Refining Targeted Therapy Opportunities for BRAF-Mutant Melanoma
Jenkins, R. W., & Barbie, D. A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0607 · Cited by 7
Vidarsdóttir, L., Fernandes, R. V., Zachariadis, V., Das, I., Edsbäcker, E., Sigvaldadóttir, I., Azimi, A., Höiom, V., Hansson, J., Grandér, D., et al. (2020) · Melanoma Research · doi:10.1097/cmr.0000000000000675 · Cited by 6
Growth factor transduction pathways: paradigm of anti-neoplastic targeted therapy
Carlomagno, F., & Chiariello, M. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1177-7 · Cited by 7
“Also up-regulation of PDGFRB function can activate, in a mutant BRAF-independent manner, the MAP kinase cascade and promote resistance [46] (Table 1), with a recent demonstration that reactivation of TGFβ signaling causes upregulation of EGFR and PDGFRB and resistance to BRAF and MEK inhibitors [50].”
BackgroundNiculescu, V. F. (2018) · Journal of Cancer Genetics and Biomarkers · doi:10.14302/issn.2572-3030.jcgb-18-2183 · Cited by 6
“differentiated somatic cells (co-existing together) and the second is the reversibility of phenotype switching in the tumor cell population [45-47].”
BackgroundMechanisms of melanoma resistance to treatment with BRAF and MEK inhibitors
Bartnik, E., Fiedorowicz, M., & Czarnecka, A. M. (2019) · Nowotwory Journal of Oncology · doi:10.5603/njo.2019.0025 · Cited by 7
KIM, G., Bhattarai, P. Y., Oh, C., & Choi, H. S. (2019) · Anticancer Research · doi:10.21873/anticanres.13869 · Cited by 7
Dent, P., Booth, L. A., Poklepovic, A. S., & Kirkwood, J. M. (2021) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13014 · Cited by 6
“* p < .05 less than corresponding [neratinib + HDAC inhibitor] values in MEL1/2/4 cells TA B L E 1 Regulation of cell signaling processes by neratinib and sodium valproate M1, V NER VAL N + V M2, V NER VAL N + V M4, V NER VAL N + V P- ATM 100 118# 102 123# 100 124# 103 126# 100 109 101 116# P- AMPK 100 120# 100 130# 1…”
BackgroundMao, F., Wu, S., Allison, D. B., He, D., Kong, Y., Li, C., Li, Z., Zhang, Y., Wang, X., Zhang, Q., et al. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3003490 · Cited by 6
“However, the overall duration of response to Vemurafenib is relatively limited, lasting only about 6 months [6,7].”
Xie, Y., Li, Y., Tang, M., Li, Z. Z., Hu, W., Qiu, X., Wang, C., Zou, Y., Lu, J. J., Yuan, Z., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03623-0 · Cited by 6
Bouamri, L. E., Laaouina, S., Lakrim, I., Nour, H., Yamari, I., Samadi, A., Bouachrıne, M., & Chtita, S. (2026) · Pharmaceuticals · doi:10.3390/ph19020315 · Cited by 6
“BRAF V600E, particularly this V600E mutation, is a driver of melanomagenesis and has been implicated in aggressive skin cancer phenotypes [61].”
Hartman, M. L., Koziej, P., Kluszczyńska, K., & Czyż, M. (2023) · Cancers · doi:10.3390/cancers15194799 · Cited by 6
“Acquired resistance to targeted therapies is a serious clinical problem [18,54,55].”
Muraro, E., Montico, B., Lum, B., Colizzi, F., Giurato, G., Salvati, A., Guerrieri, R., Rizzo, A., Comaro, E., Canzonieri, V., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1336566 · Cited by 5
“Notably, the analysis of TCGA data con fi rmed a signi fi cantly higher expression of transcripts of several RTKs and RTK ligands, including EGFR and NRG1, as well as transcription factors positively associated to BRAFi resistance in CM samples predicted to be intrinsically resistant to BRAFi (Supplementary Figure 2) ba…”
InfluentialDummer, R., Sandhu, S. K., Miller, W. H., Butler, M. O., Taylor, M. H., Heinzerling, L. M., Blank, C. U., Muñoz‐Couselo, E., Burris, H. A., Postow, M. A., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0254 · Cited by 6
“Potential methods for overcoming kinase inhibitor resistance remain a key area of focus within the melanoma landscape (49).”
Self-citationMicroenvironment-Driven Resistance to BRAF Inhibition Comes of Age
Menon, D. R., & Schaider, H. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.373 · Cited by 6
SOX7 promotes the maintenance and proliferation of B cell precursor acute lymphoblastic cells
Cuvertino, S., Filiciotto, G., Masurekar, A. N., Saha, V., Lacaud, G., & Kouskoff, V. (2016) · Oncotarget · doi:10.18632/oncotarget.10472 · Cited by 5
Maik-Rachline, G., Cohen, I., & Seger, R. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_5 · Cited by 6
With great power comes great vulnerability
de Oliveira, R. L., Wang, L., & Bernards, R. (2018) · Molecular & Cellular Oncology · doi:10.1080/23723556.2018.1509488 · Cited by 5
“Indeed, in melanoma, this drug withdrawal after the acquisition of resistance to MAPKi has been shown to induce hallmarks of oncogene-induced senescence due to hyperactivation of MAPK pathway signaling.(8) This also points towards an acquired vulnerability of drug-resistant cells that was not present in the parental s…”
BackgroundSelf-citationRebecca, V. W., Xiao, M., Kossenkov, A. V., Godok, T., Brown, G. S., Fingerman, D., Alicea, G. M., Wei, M., Ji, H., Portuallo, M. E., et al. (2026) · iScience · doi:10.1016/j.isci.2026.114669 · Cited by 5
Rare, yet relevant tumor cells – A new twist to melanoma cell plasticity
Zingg, D., & Sommer, L. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12643 · Cited by 5
“However, a large fraction of patients suffer from intrinsic or acquired resistances to these therapeutics and eventually display progressing disease (Hugo et al., 2015; Sharma, HuLieskovan, Wargo, & Ribas, 2017; Sun et al., 2014).”
BackgroundResultInfluentialEpigenetics in Melanoma Development and Drug Resistance
Hammerlindl, H., & Schaider, H. (2018) · InTech eBooks · doi:10.5772/intechopen.70983 · Cited by 5
“Elevated EGFR and PDGFRβ levels have been shown to be reversible after discontinuing BRAF and MEK inhibitor treatment, while expression of EGFR or treatment with TGF-β resulted in a slow cycling drug-resistant phenotype [72].”
BackgroundPhase I Trial of Dabrafenib and Pazopanib in BRAF Mutated Advanced Malignancies
Haraldsdóttir, S., Jankú, F., Poi, M. J., Timmers, C. D., Geyer, S. M., Schaaf, L. J., Sexton, J., Wei, L., Thurmond, J., Velez-Bravo, V. M., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00247 · Cited by 5
Tétu, P., Vercellino, L., de Moura, C. R., Baroudjian, B., Dumaz, N., Mourah, S., & Lebbé, C. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000706 · Cited by 5
“[6] demonstrated that a gain in EGFR expression in BRAF-mutated melanoma cells treated with BRAF and MEK inhibitors resulted from an adaptive but reversible drug resistance mechanism.”
BackgroundInfluentialAlver, T. N., Heintz, K., Hovig, E. J., & Bøe, S. L. (2022) · Cancer Reports · doi:10.1002/cnr2.1736 · Cited by 6
“suggested to desensitize BRAF-mutant melanoma to MAPK inhibition, however, loss of SOX10 has also been shown to drive acquired resistance.(2,11) The lack of MITF and its upstream regulator SOX10 has also”
BackgroundAjiro, M., & Zheng, Z. (2015) · Cell & Bioscience · doi:10.1186/s13578-015-0061-7 · Cited by 5
Targeting Minimal Residual Disease
Chou, Y., Allegakoen, P., & Bivona, T. G. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070924-120742 · Cited by 7
Chen, J., Zhang, L., Pu, Y., Chen, Y., Li, Y., Pan, X., & Chen, J. (2023) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520623666230503094517 · Cited by 4
Amaral, T. M. S., Pop, O. T., Chatziioannou, E., Sinnberg, T. W., Niessner, H., Zhao, J., Ring, S. S., Joerger, M., Schroeder, C., Armeanu–Ebinger, S., et al. (2023) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2023.06.057 · Cited by 4
Acquired and intrinsic resistance to vemurafenib in BRAF V600E ‐driven melanoma brain metastases
Zhang, P., Kuil, L. E., Buil, L. C. M., Freriks, S., Beijnen, J. H., van Tellingen, O., & de Gooijer, M. C. (2023) · FEBS Open Bio · doi:10.1002/2211-5463.13730 · Cited by 4
“Upstream growth factor receptors are likely candidates for such a mechanism and have been demonstrated to mediate resistance to BRAF V600 inhibitors before [31 – 34].”
BackgroundInfluentialMiguel, P. A.-D., Muñoz‐Couselo, E., Gutiérrez-Sanz, L., Fernández, L. A., Navarro-Pérez, V., Berciano‐Guerrero, M., García-Arroyo, F. R., Aguado, C., Cerezuela-Fuentes, P., Majem, M., et al. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-04005-w · Cited by 4
“It was proposed that patients who develop resistance to BRAF/MEKi may benefit from a TFI from TT [15].”
Han, J., Jung, Y., Jun, Y., Park, S., & Lee, S. (2021) · Genomics & Informatics · doi:10.5808/gi.20074 · Cited by 5
“Next, we examined the gene expression of pathway marker genes that are known to be associated with vemurafenib resistance, including the RTK pathway [28], transforming growth factor β (TGF-β) pathway [29], MITF regulation [30], Sonic hedgehog pathway [31], MAPK pathway [32-34], and PI3K-AKT-mTOR pathway [11,35] (Fig.”
BackgroundVaeyens, F., Hetzel, J.-P., Abdullah, K., Eggermont, C., Olsen, C., Mernberger, M., Maes, K., Vlaeminck, J., Claus, R., Vanisterbecq, D., et al. (2026) · International Journal of Cancer · doi:10.1002/ijc.70558 · Cited by 4
Darkening and eruptive nevi during treatment with erlotinib.
Hemperly, S., Ermolovich, T., Lountzis, N. I., Sheikh, H. A., & Purcell, S. M. (2019) · PubMed · Cited by 4
Shi, R., Nejad, M. I., Zhang, X., Gu, L., & Gates, K. S. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00663 · Cited by 4
Promising Strategies for Overcoming BRAF Inhibitor Resistance Based on Known Resistance Mechanisms
Li, Q.-S., Shen, B.-N., Xu, H., & Ruan, B. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200422073622 · Cited by 4
Lopes, B. A., Ortelan, A. G., Faria, A. V. D. S., & Ferreira‐Halder, C. V. (2020) · Brazilian Journal of Health Review · doi:10.34119/bjhrv3n4-291 · Cited by 4
Non‐genetic and genetic rewiring underlie adaptation to hypomorphic alleles of an essential gene
Targa, A., Larrimore, K. E., Wong, C. K., Chong, Y. L., Fung, R., Lee, J., Choi, H., & Rancati, G. I. (2021) · The EMBO Journal · doi:10.15252/embj.2021107839 · Cited by 4
“In other cases, the drug-resistant phenotype was shown to be unstable and lost upon drug withdrawal (Knoechel et al , 2014; Sun et al , 2014).”
The role of palbociclib in thyroid carcinoma with BRAF mutation
Tsoukalas, N., Tsapakidis, K., & Alexandraki, K. (2018) · Gland Surgery · doi:10.21037/gs.2018.03.07 · Cited by 5
“ERK stimulation induce pro-growth and transforming factors, through its interaction with a number of molecules, which appears to be critical for the development of many cancers (21).”
BackgroundGuay, J., Kuasne, H., Chabot, C., Bozek, K., Majedi, Y., Buchanan, M., Aguilar‐Mahecha, A., Bareke, E., Ulmer, B., Kong, T., et al. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0044 · Cited by 3
Self-citationWang, Y., Ohnuki, H., Tran, A. D., Wang, D., Ha, T., Feng, J., Sim, M., Barnhill, R. L., Lugassy, C., Sargen, M. R., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci181609 · Cited by 3
“Despite therapeutic advances, BRAFV600E-mutant metastatic melanoma develops resistance to BRAFV600E inhibitors after initially responding (4, 5), and colorectal cancers are often intrinsically resistant to BRAF kinase inhibitors, underscoring the need to identify potential routes of drug resistance…”
Systems biology successes and areas for opportunity in prostate cancer
Orman, M. V., Graham, L. S., Cramer, S. D., & Costello, J. C. (2025) · Endocrine Related Cancer · doi:10.1530/erc-25-0067 · Cited by 4
“There is active research to expand this approach to other cancer types, including in melanoma (79, 80, 81), breast (82, 83), colorectal (84), and ovarian cancers (85).”
Dian, A. L., Fabbri, L., Moya‐Plana, A., Claps, G., Ferreira, J. C., Labbé, C. M., Quidville, V., Martineau, S., Baïlle, D., Besse, L., et al. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3003364 · Cited by 3
“Besides, while SOX10 knockdown has been shown to promote cell migration, it has also been demonstrated to decrease melanoma cell proliferation and clonogenicity [28,46,47].”
Self-citationOura, K., Morishita, A., Nakahara, M., Tadokoro, T., Fujita, K., Tani, J., Masaki, T., & Kobara, H. (2025) · Cancers · doi:10.3390/cancers17183052 · Cited by 3
“Resistance to dabrafenib and trametinib in BRAF-mutant melanoma has been widely investigated, revealing diverse mechanisms [165].”
Chiheb, C., Fischer, S., Ahmad, Z. E., Henz, I., Böhme, I., Kappelmann‐Fenzl, M., & Bosserhoff, A. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02806-0 · Cited by 3
“Mycoplasma contamination of the cell lines was excluded every 3 months using PhoenixDx Mycoplasma Mix (PCCSKU15209, Procomcure Biotech Germany GmbH, Hamburg, Germany).”
MAPK Inhibitor‐Tolerant Persister Cells in Melanoma: Mechanisms and Therapeutic Vulnerabilities
Shah, B., Mayhew, M. M., Sellers, J., & Witt, R. G. (2026) · Cancer Science · doi:10.1111/cas.70418 · Cited by 4
On fitness: how do mutations shape the biology of cancer?
Majewski, I. J. (2019) · Biochemical Society Transactions · doi:10.1042/bst20180224 · Cited by 3
McClure, E., Patel, A. S., Carr, M. J., Sun, J. X., & Zager, J. S. (2021) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2021.1847639 · Cited by 3
Park, H., Yamaguchi, R., Imoto, S., & Miyano, S. (2022) · Journal of Computational Biology · doi:10.1089/cmb.2021.0314 · Cited by 3
“SOX10 Previous studies have also revealed the SOX10 -related mechanisms of BRAF inhibitor resistance: SOX10 activates not only EGFR but also ERBB3 , whereas loss of SOX10 leads to increased EGFR expression and vemurafenib resistance (Sun et al., 2014).”
463 PTPN11 is a central node in intrinsic and acquired resistance to targeted cancer drugs
Prahallad, A. (2014) · European Journal of Cancer · doi:10.1016/s0959-8049(14)70589-1 · Cited by 3
Self-citationAntioxidant and Anticancer Properties of the Extracts from Lepisorus thunbergianus (Kaulf.) Ching
Yang, J., Kwon, Y. S., Lim, J. D., Yu, C. Y., & Kim, M. J. (2015) · Korean Journal of Medicinal Crop Science · doi:10.7783/kjmcs.2015.23.4.324 · Cited by 3
Melanoma-derived induced pluripotent stem cells
Castro‐Pérez, E., Sadangi, S., Singh, M. K., & Setaluri, V. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822135-8.00012-4 · Cited by 4
Misek, S., Appleton, K. M., Dexheimer, T. S., Lisabeth, E. M., Lo, R. S., Larsen, S. D., Gallo, K., & Neubig, R. R. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/381806 · Cited by 3
“Another study demonstrated that Sox10 silencing promotes BRAFi resistance, in part through activation of TGFβ signaling (43).”
BackgroundGambaro, K., Marques, M., McNamara, S., du Tertre, M. C., Hoffert, C., Srivastava, A., schab, A., Alcindor, T., Langleben, A., Sidéris, L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010043 · Cited by 2
Pre-existing cell states predict resistance to multiple treatments
Schaff, D. L., White, P. E., Cote, C. J., Watterson, G., Lin, K. Z., Fasse, A. J., Zhang, N. R., & Shaffer, S. M. (2026) · Cell Genomics · doi:10.1016/j.xgen.2026.101191 · Cited by 2
“16,20,55,57 Notably, the dabrafenib and trametinib resistance programs were not restricted to clusters 2 and 7, which had high EGFR , NGFR , and AXL expression.”
Metadata
- Authors
- Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., Zecchin, D., Hobor, S., Bajpe, P. K., Lieftink, C., Mateus, C., Vagner, S., Grernrum, W., Hofland, I., Schlicker, A., Wessels, L. F. A., Beijersbergen, R. L., Bardelli, A., Di Nicolantonio, F., Eggermont, A. M. M., & Bernards, R.
- Affiliations
- The Netherlands Cancer Institute (NL)
- Institut Gustave Roussy (FR)
- Candiolo Cancer Institute (IT)
- IFOM (IT)
- ORCID
- Sun, Chong
- Wang, Liqin
- Huang, Sidong
- Heynen, Guus J. J. E.
- Prahallad, Anirudh
- Robert, Caroline
- Haanen, John
- Blank, Christian
- Wesseling, Jelle
- Willems, Stefan M.
- Zecchin, Davide
- Lieftink, Cor
- Hofland, Ingrid
- Schlicker, Andreas
- Wessels, Lodewyk F. A.
- Beijersbergen, Roderick L.
- Bardelli, Alberto
- Eggermont, Alexander M. M.
- Venue
- Nature
- Published
- 2014-03-26
- Volume
- 508
- Issue
- 7494
- Pages
- 118-122
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1985928174
- Cited by
- 888
- References
- 30
- Citations by year
- 2026: 29 · 2025: 43 · 2024: 62 · 2023: 58 · 2022: 90 · 2021: 81 · 2020: 71 · 2019: 76 · 2018: 75 · 2017: 83 · 2016: 71 · 2015: 107 · 2014: 39
- FWCI
- 40.97
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Canadian Institutes of Health Research (MOP130540)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- BRAF inhibitor resistance, SOX10, TGF-beta signaling, PDGFRβ, oncogene-induced senescence, drug holidays, MEK inhibitors, adaptive resistance, shRNA screen, cell proliferation, tumor heterogeneity, drug re-sensitization, receptor tyrosine kinase
- MeSH terms
- Vemurafenib, Animals, Antineoplastic Agents, Female, Flow Cytometry, Humans, Indoles, Melanoma, Sulfonamides, Signal Transduction, Gene Library, Gene Expression Regulation, Neoplastic, Transforming Growth Factor beta, Cellular Senescence, Drug Resistance, Neoplasm, Receptor Protein-Tyrosine Kinases, Receptor, Platelet-Derived Growth Factor beta, Mitogen-Activated Protein Kinase Kinases, RNA, Small Interfering, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Cell Proliferation, Mice, SOXE Transcription Factors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.